презентация по красной книге 2 класс окружающий мир
Главное меню:
Интересное
презентация по красной книге 2 класс окружающий мир, Marijuana, Inc., Completes Acquisition of Exousia AI and , OTC Markets | Official site of OTCQX, OTCQB and Pink Markets, Exousia Pro Finishes Preclinical Trial for Glioblastoma Ahead , Marijuana, Inc., Completes Acquisition of Exousia AI and , Exousia Pro Files Reg A. - Yahoo Finance, Exousia Pro Files Reg A. | FinancialContent, Exousia Pro Files Reg A. - streetinsider.com.
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements do not guarantee future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately price, retain, and complete projects and changes in products and competition., Exousia AI is involved in other studies, including one study concluding in Italy. Exousia Pro will enter two additional studies covering dermatology and the dental market that are part of the acquisition. Exousia Pro will manufacture and sell vials of wet exosomes or jars of dried exosomes to the nutraceutical and dermatology markets., Stay up to date on the latest company news, industry trends and regulatory changes that affect our markets and learn about members of our community..
Exousia Pro is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes via the targeted delivery of nuclear material. Initially the therapeutic focus will be on oncology, the company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of , Exousia Pro will manufacture and sell vials of wet exosomes or jars of dried exosomes to the nutraceutical and dermatology markets. The OTC exosome market, known as cosmeceuticals, is rapidly , Exousia Pro intends to conduct its Reg A offering in a drastically different manner than the typical OTC company. Instead, the Company plans to stay true to the offering price of the Reg A, that , Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's patented manufacturing process utilizes plant-based materials to create exosomes used in a number of commercial applications, from dermatology to , Exousia Pro (formerly Marijuana, Inc.) is a clinical-stage biotechnology company developing new ways to exploit the therapeutic potential of exosomes, initially focused on oncology. The company's , .